Promising drug cocktail aims to save voice boxes in throat cancer patients

NCT ID NCT07665190

Recruiting now Disease control Sponsor: Tianjin Medical University Cancer Institute and Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This phase II trial tests two drugs—becotatug vedotin and pucotenlimab—given before surgery to people with advanced hypopharyngeal cancer. The goal is to shrink tumors enough to improve surgical outcomes and possibly preserve the voice box. About 52 participants will receive three cycles of the combination, and researchers will measure how many have no cancer cells left in the removed tissue.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: becotatug vedotin and pucotenlimab (drug combination)
What this could lead to: If successful, this combination could shrink tumors before surgery, potentially allowing more patients to avoid removal of the voice box and improve long-term survival.
What could go wrong: This is an early phase II trial with only 52 participants, so results may not apply to all patients. The drugs can cause side effects like infusion reactions or immune-related inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypopharynx squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA

Contacts and locations

Locations

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin 300000
RECRUITING

Tianjin, Tianjin Municipality, 300060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.